UBS maintains its neutral recommendation on the stock with a target price of €87 after the presentation of the quarterly figures. The analyst considers the first-quarter results in America and Europe to be disappointing.

Organic sales for the first quarter were down 7.6% compared with the 7.1% forecast, due to destocking in the United States and underlying weakness in Europe and Latin America. China and India are not as badly affected as expected,' the research firm points out.

In the medium term (2026/27-2028/29), the group expects its organic revenue growth to improve to an average range of +3% to +6%, as well as an increase in its organic operating margin.

At the current price, the stock has a 2025 P/E ratio of around 14 times with a yield of nearly 5%.